J Gynecol Oncol | Volume 2, Issue 1 | Review Article | Open Access
Minakshi Rohilla* and Tanuja Muthyala
Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research, India
*Correspondance to: Minakshi Rohilla
Fulltext PDFManagement of Carcinoma breast with metastatic disease in premenopausal woman is expanding from tamoxifen only to additional ovarian suppression with Gonadotropin Releasing Hormone agonists (GnRh), Aromatase inhibitors and or bilateral oophorectomy. Direct comparison or therapeutic superiority of medical vs. surgical ovarian suppression is reported in very few studies. This review focuses on consensus of recent articles on the benefits and risks of medical versus surgical ovarian suppression in perimenopausal women with non-hereditary and hormone receptor positive metastatic breast cancer. Surgical ovarian ablation seems to be cost-effective to medical therapy as adjuvant therapies in metastatic breast cancer with add on benefit of preventing ovarian cancer. However counseling regarding side-effects, risk-benefit ratio and quality-of-life after surgical menopause need to be addressed.
Rohilla M, Muthyala T. Current Concepts in Role of Bilateral SalpingoOophorectomy in Non-Hereditary Metastatic Carcinoma of Breast: Review Article. J Gynecol Oncol. 2019; 2(1): 1008.